Abstract
The pharmacokinetics of Δ 9 -tetrahydrocannabinol (THC) administered intravenously was evaluated in four subjects after oral administration of placebo and 1500 mg of cannabidiol (CBD) according to a crossover design. The cannabidiol pretreatment had no apparent effect on THC pharmacokinetics, yet there may have been minimal effect on the formation and excretion of metabolites. The total (metabolic) blood clearance of THC averaged 17.4 ml/min/kg without CBD and 20.9 ml/min/kg with CBD, and was probably hepatic blood flow limited. The apparent steady-state volume of distribution averaged 9.86 (with CBD, 10.54) liters/kg. Irrespective of CBD pretreatment, the renal clearance of THC metabolites ranged from 17 ml/min after approximately 1 hr to 1.13 ml/min 3.5days after dosing with THC. The apparent terminal half life for metabolites averaged 8.2 days.
Similar content being viewed by others
References
R. Mechoulam, A. Shani, E. Edery, and Y. Greenfield. Chemical basis of hashish activity.Science 169:611–612 (1970).
M. Perez-Reyes, M. C. Timmons, K. H. Davis, and E. M. Wall. A comparison of the pharmacological activity in man of intravenously administered Δ9-tetrahydrocannabinol, cannabinol and cannabidiol.Experientia 29:1368–1369 (1973).
S. A. Turkanis, W. Caley, D. M. Olsen, and R. Karler. Anticonvulsant properties of cannabidiol.Res. Commun. Chem. Pathol Pharmacol. 8:231–246 (1974).
W. S. Dalton, R. Martz, L. Lemberger, B. E. Rodda, and R. B. Forney. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects.Clin. Pharmacol. Ther,19:300–309 (1976).
W. D. M. Paton and R. G. Pertwee. Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism.Br. J. Pharmacol. 44:250–261 (1972).
A. J. Siemans, H. Kalant, and J. C. deNie. Metabolic interactions between delta-9-tetrahydrocannabinol and other cannabinoids in rats. In M. C. Braude and S. Szara (eds.),The Pharmacology of Marihuana, Raven Press, New York, 1976, pp. 77–92.
B. B. Caldwell, K. Bailey, C. J. Paul, and G. Anderson. Interaction of cannabinoids with pentobarbital in rats.Toxicol. Appl. Pharmacol. 29:59–69 (1974).
G. Jones and R. G. Pertwee. A metabolic interactionin vivo between cannabi'nol and delta-1-tetrahydrocannabinol.Br. J. Pharmacol. 45: 375–377 (1972).
A. J. Siemens, H. Kalant, J. M. Khanna, J. Marshman, and G. Ho. Effect of cannabis on pentobarbital-induced sleeping time and pentobarbital metabolism in the rat.Biochem. Pharmacol. 23:477–488 (1974).
N. L. Benowitz, T. L. Nguyen, R. T. Jones, R. I. Herning, and J. Bachman. Metabolic and psychophysiologic studies of cannabidiol-hexobarbitai interaction.Clin. Pharmacol. Ther. 28:115–120(1980).
W. S. Dalton, R. Martz, B. E. Rodda, L. Lemberger, and R. B. Forney. Influence of cannabidiol on secobarbital effects and plasma kinetics.Clin. Pharmacol. Ther. 30:695–700 (1976).
B. E. Belgrave, K. D. Bird, and G. B. Chesher. The effect of cannabidiol, alone and in combination with ethanol, on human performance.Psychopharmacology 64:243–246 (1979).
L. E. Hollister and H. Gillespie. Interactions in man of Δ9-tetrahydrocannabinol. I. Cannabinol and cannabidiol.Clin. Pharmacol. Ther. 18:80–93 (1975).
I. G. Karniol, I. Shirakawa, N. Kasinski, A. Pfeferman, and I. G. Carlini. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man.Eur. J. Pharmacol. 28:172–177 (1974).
C. A. Hunt and R. T. Jones. Tolerance and disposition of tetrahydrocannabinoi in man.J. Pharmacol. Exp. Ther. 215:35–44 (1981).
R. T. Jones, N. Benowitz, and J. Bachman. Clinical studies of cannabis tolerance and dependence.Ann. N. Y. Acad. Sci. 282:221–239 (1976).
E. R. Garrett and C. A. Hunt. Separation and analysis of Δ9-tetrahydrocannabinol in biological fluids by high-pressure liquid chromatography and GLC.J. Pharm. Sci. 66:20–26 (1977).
E. R. Garrett, A. J. Gouyette, and C. A. Hunt. GLC and HPLC analysis of cannabinoids in biological fluids and applications. In J. A. Vinson (ed.),Cannabinoid Analysis in Physiological Fluids, ACS Symposium Series 98, Am. Chem. Soc., Washington, D.C., 1979, pp. 13–37.
L. Lemberger, N. R. Tamarkin, J. Axelrod, and I. J. Kopin. Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marijuana users.Science 173:72–74 (1971).
L. Z. Benet. General treatment of linear mammallary models with elimination from any compartment as used in pharmacokinetics.J. Pharm. Sci. 61:536–541 (1972).
E. R. Garrett and C. A. Hunt. Pharmacokinetics of delta-9-tetrahydrocannabinol in dogs.J. Pharm. Sci. 66:395–407 (1977).
C. M. Metzler.A User's Manual for NONLIN, The Upjohn Co., Technical Report 7292/69/7292/005, 1969, Kalamazoo, Mich.
D. S. Riggs.The Mathematical Approach to Physiological Problems, 2nd edn. M.I.T. Press, Cambridge, Mass., 1972, pp. 146–161.
J. G. Wagner. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from coefficients and exponents of polyexponential equations which have been fitted to the data.J. Pharmacokin. Biopharm. 4:443–467 (1976).
M. Wahlquist, I. M. Nilsson, F. Sandberg, S. Agurell, and B. Granstrand. Binding of delta-1-tetrahydrocannabinol to human plasma proteins.Biochem. Pharmacol. 19:2579–2584 (1970).
E. R. Garrett and C. A. Hunt. Physicochemical properties, solubility and protein binding of delta-9-tetrahydrocannabinol.J. Pharm. Sci. 63:1056–1064 (1974).
N. K. McCallum and M. E. Eastwood.In vivo binding of delta-1-tetrahydrocannabinol and cannabinol to rat serum proteins.J. Pharm. Pharmacol. 30:384–386 (1978).
K. O. Fehr and H. Kalant. Fate of14C-delta-1-THC in rat plasma after intravenous injection and smoking.Eur. J. Pharmacol. 25:1–8 (1974).
F. C. Law. Metabolism and disposition of Δ1 -tetrahydrocannabinol by the isolated perfused rabbit lung.Drug Metab. Dispos. 6:154–163 (1978).
G. R. Wilkinson and D. G. Shand. A physiological approach to hepatic drug clearance.Clin. Pharmacol. Ther. 18:377–379 (1975).
H. K. Borys, G. B. Ingall, and R. Karler. Development of tolerance to the prolongation of hexobarbitone sleeping time caused by cannabidiol.Br. J. Pharmacol. 67:93–101 (1979).
Author information
Authors and Affiliations
Additional information
This work was supported by National Institute on Drug Abuse Grant DA-01773, Program Project Grant DA-01696 and Contract No. HSM-42-73-181.
Recipient of National Institute on Drug Abuse Research Scientist Award DA-00053.
Rights and permissions
About this article
Cite this article
Hunt, C.A., Jones, R.T., Herning, R.I. et al. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. Journal of Pharmacokinetics and Biopharmaceutics 9, 245–260 (1981). https://doi.org/10.1007/BF01059266
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059266